Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to single operating segment which is the manufacture and sale of biologicals, medical hyaluronate and intraocular lens, research and development of biological engineering and pharmaceutical products and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	12.81
Equity-to-Asset	0.8
Debt-to-Equity	0.04
Debt-to-EBITDA	0.41
Interest Coverage	49.54
Piotroski F-Score	N/A/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.95	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	24
	3-Year EBITDA Growth Rate	20.1
	3-Year EPS without NRI Growth Rate	20.1
	3-Year FCF Growth Rate	74.6
	3-Year Book Growth Rate	-0.5
	Future 3-5Y Total Revenue Growth Rate	19.16

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	70.96
	9-Day RSI	63.74
	14-Day RSI	60.95
	6-1 Month Momentum %	11.83
	12-1 Month Momentum %	32.97

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.43
	Quick Ratio	4.66
	Cash Ratio	3.95
	Days Inventory	244.69
	Days Sales Outstanding	50.18
	Days Payable	34.87

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.41
	Dividend Payout Ratio	0.16
	3-Year Dividend Growth Rate	-18.7
	Forward Dividend Yield %	3.41
	5-Year Yield-on-Cost %	3.11
	3-Year Average Share Buyback Ratio	1.2
	Shareholder Yield %	2.05

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	69.79
	Operating Margin %	16.58
	Net Margin %	16.19
	FCF Margin %	-11.81
	ROE %	7.58
	ROA %	6.04
	ROIC %	9.06
	ROC (Joel Greenblatt) %	26.78
	ROCE %	7.99
	Years of Profitability over Past 10-Year	10

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	16.17
	PE Ratio without NRI	16.28
	Shiller PE Ratio	18.78
	Price-to-Owner-Earnings	50.32
	PS Ratio	2.62
	PB Ratio	1.21
	Price-to-Tangible-Book	1.51
	Price-to-Operating-Cash-Flow	91.4
	EV-to-EBIT	20.15
	EV-to-Forward-EBIT	29.08
	EV-to-EBITDA	20.15
	EV-to-Forward-EBITDA	19.27
	EV-to-Revenue	3.92
	EV-to-Forward-Revenue	5.46
	EV-to-FCF	-33.18
	Price-to-Projected-FCF	0.87
	Price-to-Graham-Number	1.05
	Price-to-Net-Current-Asset-Value	3.03
	Price-to-Net-Cash	5.41
	Earnings Yield (Greenblatt) %	4.96
	FCF Yield %	-2.51

GF Value: HK$38.4

HKSE:06826

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 06826. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.